Search results
Results from the WOW.Com Content Network
While men are less likely to develop osteoporosis, it is possible and has been occurring more often in recent years in men over age 65. “Most men should aim for 1,000 - 1,200mg of calcium per ...
Denosumab, sold under the brand name Prolia among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone. [19] [20] The most common side effects are joint and muscle pain in the arms or legs. [21]
Prolia (denosumab) is an injectable medication that helps treat osteoporosis. Osteoporosis is a condition that causes the bones to become thin and weak, leading to a higher risk of fractures and ...
Long-term treatment with bisphosphonates produces anti-fracture and bone mineral density effects that persist for 3–5 years after an initial 3–5 years of treatment. [2] The bisphosphonate alendronate reduces the risk of hip, vertebral, and wrist fractures by 35-39%; zoledronate reduces the risk of hip fractures by 38% and of vertebral ...
Prolia, approved in 2010 to treat bone loss in postmenopausal women and later approved to treat men and women at high risk of fracture, brought in total third-quarter sales of $986 million.
Romosozumab, sold under the brand name Evenity (/ ɪ ˈ v ɛ n ɪ t i / ih-VENN-ih-tee or with the pin-pen merger, / ɪ ˈ v ɪ n ɪ t i / ih-VINN-ih-tee), is a medication used to treat osteoporosis. [7] [8] It has been found to decrease the risk of fractures of the spine. [7] Common side effects include headache, joint pain, and injection site ...
Teriparatide is indicated for the treatment of postmenopausal women with osteoporosis; [13] for the increase of bone mass in men with primary or hypogonadal osteoporosis; [13] and treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy.
Treatment of osteoporosis or non-malignant bone disease with denosumab (not taking systemic glucocorticoids) High: Patients being treated for osteoporosis or non-malignant bone disease with oral bisphosphonates/quarterly or yearly infusions of intravenous bisphosphonates for >5 years